ARCHIVES

Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction.

This article is from The Cancer Letter archive.

Vol. 32 No. 15 | April 21, 2006

Download PDF Visit The Full Archive

Related Articles

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

December 30, 2011

ACS Modifies Pap Test Guidelines

November 27, 1987

Olaparib Study Demonstrates No Changes In Overall Survival

March 30, 2012

Dugan Head ACCC, Yarbro President Elects; Amos Honored

March 18, 1983

Announcement, RFA On Drug Discovery Groups Coming

December 10, 1982

FDA Approves Rituxan For NHL With CHOP Therapy

February 24, 2006